Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Padmanabh P. Bhatt Sells 9,477 Shares of Stock

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Padmanabh P. Bhatt sold 9,477 shares of Supernus Pharmaceuticals stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total value of $376,236.90. Following the completion of the sale, the vice president now directly owns 10,149 shares of the company’s stock, valued at $402,915.30. The trade was a 48.29 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Supernus Pharmaceuticals Trading Down 1.3 %

Shares of NASDAQ:SUPN opened at $39.48 on Thursday. The stock has a 50 day moving average of $37.29 and a 200 day moving average of $34.69. The company has a market cap of $2.18 billion, a PE ratio of 36.90 and a beta of 0.90. Supernus Pharmaceuticals, Inc. has a 12-month low of $25.53 and a 12-month high of $40.28.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.25. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. The firm had revenue of $175.70 million during the quarter, compared to analysts’ expectations of $157.35 million. During the same period in the prior year, the company posted ($0.29) earnings per share. The company’s revenue for the quarter was up 14.2% compared to the same quarter last year. Equities research analysts predict that Supernus Pharmaceuticals, Inc. will post 2.38 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Cantor Fitzgerald started coverage on shares of Supernus Pharmaceuticals in a research report on Monday, January 6th. They set an “overweight” rating and a $57.00 price target for the company. Piper Sandler reiterated a “neutral” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Finally, Cowen reissued a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th.

Institutional Investors Weigh In On Supernus Pharmaceuticals

A number of institutional investors have recently bought and sold shares of SUPN. Stephens Investment Management Group LLC boosted its stake in shares of Supernus Pharmaceuticals by 1.8% in the third quarter. Stephens Investment Management Group LLC now owns 1,932,209 shares of the specialty pharmaceutical company’s stock worth $60,246,000 after acquiring an additional 33,710 shares during the period. Pacer Advisors Inc. lifted its holdings in Supernus Pharmaceuticals by 29.9% in the 3rd quarter. Pacer Advisors Inc. now owns 1,752,882 shares of the specialty pharmaceutical company’s stock worth $54,655,000 after purchasing an additional 403,028 shares in the last quarter. Geode Capital Management LLC boosted its stake in Supernus Pharmaceuticals by 5.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock worth $46,218,000 after purchasing an additional 74,438 shares during the period. Victory Capital Management Inc. grew its holdings in Supernus Pharmaceuticals by 1.1% during the 3rd quarter. Victory Capital Management Inc. now owns 742,871 shares of the specialty pharmaceutical company’s stock valued at $23,163,000 after buying an additional 7,833 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in Supernus Pharmaceuticals by 14.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 712,395 shares of the specialty pharmaceutical company’s stock valued at $22,212,000 after buying an additional 91,354 shares in the last quarter.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.